Nota de idioma: o chrome desta página está em português; o corpo longo abaixo permanece em inglês para preservar a precisão das fontes.
Oral semaglutide
Also indexed as Rybelsus · PIONEER program · tablet semaglutide
Oral semaglutide is the tablet formulation context for semaglutide. The evidence page belongs beside the molecule page because formulation and label are part of what a study actually studied.
Last reviewed 2026-09-07 · education only
O que aparece na literatura
The active molecule still acts at the GLP-1 receptor; the oral product uses a formulation designed for absorption. A tablet label should not be treated as automatic equivalence to an injectable product or research material.
History & development
- 2019
Novo Nordisk's heritage timeline identifies the first oral GLP-1 treatment for type 2 diabetes, and PIONEER 1 reported randomized trial results for oral semaglutide.
Approved brands & pathway
Rybelsus
United StatesFDA-approved prescription product
Oral semaglutide product; read the current label.
Open DailyMed label search ↗Entradas de evidência
Tema: Diabetes · oral GLP-1 literacy · Categoria: Diabetes
Oral semaglutide
O que a fonte sustenta
Randomized diabetes efficacy research
PIONEER 1 compared oral semaglutide with placebo in adults with type 2 diabetes and reported HbA1c and weight endpoints.
Limite: An oral formulation and a diabetes trial do not establish equivalence to injectable products or to a research listing.
Fonte: PIONEER 1 · Diabetes Care Ler fonte ↗
Grade mix in this atlas
Grades describe the cited record for a narrow question. They do not score a marketplace material or make a health decision.
Naming curiosities & useful distinctions
- “Oral semaglutide” is a formulation description; Rybelsus is the product name.
- PIONEER is the clinical development program name, not a brand.
Formulation changes the question
A study of a tablet and a study of an injection can share an active molecule while differing in absorption, product instructions and label context.
Nomes no registro
Developer
Novo Nordisk
The company history documents the oral GLP-1 development milestone.